Wednesday, August 26, 2026

Marathon Petroleum Locks In Output From Two 150,000-Barrel Gulf Coast Fractionators Set for 2028-2029

Two natural gas liquid fractionators on the U.S. Gulf Coast will add 300,000 barrels per day of processing capacity by 2029, with Marathon Petroleum securing full output from both facilities. The infrastructure expansion supports Marathon's strategy to capture growing NGL volumes from shale production as petrochemical feedstock demand rises.

Marathon Petroleum Locks In Output From Two 150,000-Barrel Gulf Coast Fractionators Set for 2028-2029
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Marathon Petroleum has locked in all output from two fractionators scheduled to start operations on the Gulf Coast between 2028 and 2029, each processing 150,000 barrels per day of natural gas liquids.

The 300,000-barrel combined capacity represents significant new infrastructure for separating mixed NGLs into individual products like ethane, propane, and butane. Fractionators sit at a critical point in the petrochemical supply chain, converting raw NGLs from gas processing plants into refined components used in plastics manufacturing and fuel blending.

Marathon's full offtake agreement ensures stable demand for the facilities while securing feedstock for its refining and petrochemical operations. The company operates integrated assets across the value chain, including the 1.9 million-barrel-per-day refining network and midstream infrastructure through its MPLX partnership.

Gulf Coast fractionation capacity has expanded steadily since 2015 as Permian Basin and Appalachian shale production pushed NGL volumes higher. U.S. NGL output reached 6.5 million barrels per day in 2024, with ethane and propane exports driving demand for additional processing capacity near export terminals.

The timing aligns with expected growth in petrochemical demand. Global ethylene capacity—which uses ethane as primary feedstock—is projected to grow 3-4% annually through 2030, with much of that expansion in Asia requiring imported NGLs. U.S. producers have cost advantages due to abundant shale gas.

Marathon's commitment provides revenue certainty for the fractionator developers before construction begins. Midstream companies typically require long-term contracts covering 70-80% of capacity before greenlighting projects of this scale, which can cost $400-600 million per facility.

The Gulf Coast hosts roughly 3 million barrels per day of existing fractionation capacity, concentrated in Texas and Louisiana near major gas processing regions and export docks. These two units will add 10% to that base, suggesting continued confidence in NGL supply growth despite recent moderation in drilling activity.

Marathon has not disclosed financial terms or identified the facility operators. The company's integrated model allows it to optimize margins across gathering, processing, fractionation, and refining rather than relying solely on refining spreads.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score1 source document1 with a live linkVerifiability: Basic
  1. [1]News articleYahoo Finance· February 20, 2026
    MPLX LP: Why This Midstream MLP Deserves a Premium Valuation
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com